HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Negotiations

Amgen expands crackdown on what it says is misuse of 340B program

Amgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud and misuse of the ...

By Endpoints News · May 15, 2026 · via Endpoints News
Amgen expands crackdown on what it says is misuse of 340B program

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
negotiationsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Negotiations
All Negotiations →
NegotiationsDrug Channels ↗
PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (VIDEO)
Here at Drug Channels, we’ve been closely tracking the evolution of the pharmacy benefit management (PBM) indu…
May 20, 2026
Optum Rx unveils pharmacy model with clear fees, building on transparency push
NegotiationsEndpoints News ↗
Optum Rx unveils pharmacy model with clear fees, building on transparency push
UnitedHealth Group’s Optum Rx on Monday unveiled a new approach to prescription drug benefits that it said off…
May 11, 2026
NegotiationsDrug Channels ↗
Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels
Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx. L…
Apr 24, 2026